HARBIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.81 CNY | -1.40% |
|
-3.44% | -16.12% |
| Sales 2022 | 13.81B 1.91B | Sales 2023 | 15.46B 2.13B | Capitalization | 8.45B 1.17B |
|---|---|---|---|---|---|
| Net income 2022 | 464M 64.09M | Net income 2023 | 395M 54.56M | EV / Sales 2022 | 0.53 x |
| Net cash position 2022 | 284M 39.24M | Net cash position 2023 | 1.2B 166M | EV / Sales 2023 | 0.47 x |
| P/E ratio 2022 |
16.7
x | P/E ratio 2023 |
20.9
x | Employees | 9,853 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.57% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.40% | ||
| 1 week | -3.44% | ||
| Current month | -4.75% | ||
| 1 month | -8.17% | ||
| 3 months | -9.65% | ||
| 6 months | -17.11% | ||
| Current year | -16.12% |
1 week
2.72
2.89
1 month
2.723.07
Current year
2.413.46
1 year
2.413.90
3 years
2.413.95
5 years
2.386.53
10 years
2.3813.23
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Liu
DFI | Director of Finance/CFO | 61 | 08-09-25 |
Kun Yu Ma
IRC | Investor Relations Contact | 43 | 14-04-30 |
Xiao Dong Meng
SEC | Corporate Secretary | 52 | 04-12-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Dong Meng
SEC | Corporate Secretary | 52 | 04-12-23 |
Ai Dong Lou
BRD | Director/Board Member | 58 | 21-01-07 |
Bo Liu
DFI | Director of Finance/CFO | 61 | 08-09-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 2.81 | -1.40% | 38,187,660 |
| 24-04-17 | 2.85 | +4.01% | 37,374,740 |
| 24-04-16 | 2.74 | -3.52% | 39,380,420 |
| 24-04-15 | 2.84 | +0.35% | 43,144,390 |
| 24-04-12 | 2.83 | -2.75% | 60,705,160 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Companyâs main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -16.12% | 979M | |
| +27.97% | 672B | |
| +23.66% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.26% | 211B | |
| -0.54% | 203B | |
| -11.81% | 144B | |
| -8.80% | 141B |
- Stock Market
- Equities
- 600664 Stock
